About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 23715 record(s)
Req # A-2021-001462
Adverse Drug Reaction (ADR) for DICLOFENAC SODIUM. Report number: 000967293.Organization: Health Canada
March 2022
Req # A-2021-001465
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03709179, 000931391, E2B_03525810, E2B_03753446, E2B_03705539.Organization: Health Canada
March 2022
Req # A-2021-001470
Adverse Drug Reactions (ADRs) for Morphine. Report Numbers: E2B_04475711, E2B_04481408. ADR for Hydromorphone. Report Number: 000961041. ADR for Heparin. Report Number: E2B_04431879. ADRs for Lixiana. Report Numbers: 000916926, 000929964.Organization: Health Canada
March 2022
Req # A-2021-001484
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report Numbers: E2B_03976766, E2B_03862946, E2B_03642332, E2B_03842248, E2B_03872618, E2B_03839250, E2B_03807182, E2B_03791082, E2B_03863855, 000946805, E2B_03665842, E2B_03915037, E2B_03801631.Organization: Health Canada
March 2022
Req # A-2021-001485
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE:. Report numbers: E2B_03777823, 000950502, E2B_04053949, E2B_03979973, E2B_03686690, E2B_03932793, E2B_03966839, E2B_03575036, E2B_03966864, E2B_03966864, E2B_03575036, E2B_03630929, E2B_03706444,…Organization: Health Canada
March 2022
Req # A-2021-001490
Adverse Drug Reaction (ADR) for memantine. Report Number: E2B_03566008. ADRs for zuclopenthixol. Report Numbers: 934978 , 000935249, E2B_03556140, E2B_03581196. ADRs for flupenthixol. Report Numbers: E2B_03575675, 928306. ADRs for citalopram.…Organization: Health Canada
March 2022
Req # A-2021-001493
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report Numbers: 000949940, 000940668, E2B_03662534, E2B_04087685, E2B_03735463, E2B_03675078, E2B_03986475, E2B_03939175, E2B_03890310, E2B_03833361, E2B_03747430, E2B_03828537, E2B_04055760,…Organization: Health Canada
March 2022
Req # A-2021-001498
Adverse Drug Reactions (ADRs) for C1 ESTERASE INHIBITOR (HUMAN). Report Numbers: E2B_04457413, E2B_04457445, E2B_04475606, E2B_04396511. ADRs for LANSOPRAZOLE. Report Numbers: E2B_04444293, 000958117, 000961141, E2B_04414059.Organization: Health Canada
March 2022
Req # A-2021-001501
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report Numbers: E2B_03719656, E2B_03979980, E2B_03980276, E2B_03984207, E2B_04079533, E2B_04069939, E2B_03675432, E2B_03679403, E2B_03928984, E2B_03938531, E2B_03749288, E2B_03986623, E2B_04039411,…Organization: Health Canada
March 2022
Req # A-2021-001512
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report Numbers: E2B_03719491, E2B_03720622, E2B_03720624, E2B_03720635, E2B_03720698, E2B_03712528, E2B_03713072, E2B_03753504, E2B_03670828, E2B_03671051, E2B_03715486, E2B_03718003,…Organization: Health Canada
March 2022